Loading...
XNAS
PRPH
Market cap13mUSD
Jun 16, Last price  
0.33USD
1D
0.39%
1Q
-14.94%
Name

Prophase Labs Inc

Chart & Performance

D1W1MN
XNAS:PRPH chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.53%
Rev. gr., 5y
27.59%
Revenues
0k
-100.00%
53,658,04342,124,96939,475,38120,506,61219,816,00014,502,00017,453,00022,406,00025,032,00022,070,00020,604,00021,014,0009,867,00013,126,0009,876,00014,514,00079,042,000122,647,00044,384,0000
Net income
0k
P
3,216,684-1,748,345-2,458,337-5,534,286-3,842,000-3,501,000-2,710,000-1,091,000405,000-7,834,000-3,600,000-2,868,00041,831,000-1,740,000-3,013,000-2,420,0006,273,00018,463,000-16,782,0000
CFO
-18m
L+54.55%
4,265,489956,943-1,311,598-3,057,592445,000-3,549,000-2,108,000-5,729,0001,137,000-3,216,000-3,497,000-472,000-2,838,000-2,119,000-841,000-2,592,000-13,619,00028,551,000-11,348,000-17,538,000
Dividend
May 24, 20220.3 USD/sh
Earnings
Aug 12, 2025

Profile

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
URL
https://www.prophaselabs.com/
IPO date
Jan 16, 1984
Employees
129
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
44,384
-63.81%
122,647
55.17%
Cost of revenue
64,065
99,052
Unusual Expense (Income)
NOPBT
(19,681)
23,595
NOPBT Margin
19.24%
Operating Taxes
7,195
(6,018)
4,445
Tax Rate
18.84%
NOPAT
(7,195)
(13,663)
19,150
Net income
(16,782)
-190.90%
18,463
194.32%
Dividends
(9,353)
Dividend yield
5.21%
Proceeds from repurchase of equity
7,594
(5,967)
4,892
BB yield
-52.57%
7.67%
-2.72%
Debt
Debt current
6,568
2,793
301
Long-term debt
3,361
29,709
11,219
Deferred revenue
784
1,100
1,059
Other long-term liabilities
22,929
2,000
Net debt
9,251
27,766
(5,917)
Cash flow
Cash from operating activities
(17,538)
(11,348)
28,551
CAPEX
(906)
(3,155)
(3,919)
Cash from investing activities
2,422
(1,369)
(2,077)
Cash from financing activities
14,185
5,757
(26,023)
FCF
20,342
(20,227)
19,473
Balance
Cash
678
4,736
17,437
Long term investments
Excess cash
678
2,517
11,305
Stockholders' equity
(58,370)
(5,311)
12,526
Invested Capital
96,004
79,174
56,155
ROIC
32.80%
ROCE
34.86%
EV
Common stock shares outstanding
19,079
17,207
18,651
Price
0.76
-83.25%
4.52
-53.06%
9.63
46.58%
Market cap
14,445
-81.43%
77,776
-56.70%
179,609
48.63%
EV
23,696
105,542
173,692
EBITDA
6,644
(12,983)
28,656
EV/EBITDA
3.57
6.06
Interest
1,275
764
Interest/NOPBT
3.24%